Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1988 Sep;51(9):1146–1157. doi: 10.1136/jnnp.51.9.1146

Subacute administration of a TRH analogue (RX77368) in motorneuron disease: an open study.

H Modarres-Sadeghi 1, H Rogers 1, J Emami 1, R J Guiloff 1
PMCID: PMC1033017  PMID: 3147318

Abstract

Sixteen patients with motor neuron disease received RX77368, a TRH analogue, IV, repeatedly over 1-12 weeks (median 2 weeks). Slight to moderate improvement in bulbar function, particularly speech, was reproduced or persisted with repeated infusions in 8 of 12 responders over a median of 18 days (range 14-90) during the period of study. Cramps (5/9) and spasticity (5/8) improved for a median of 14 days (range 7-35) and 7 days (range 2-14) respectively. The highest benefit/side effect ratio was seen with 0.2 mg/kg (0.15 mg/kg in those with severe bulbar palsy) every 3-4 days. Long term studies with this analogue in MND are indicated.

Full text

PDF
1146

Images in this article

1154Image
on p.1154

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Braun S. R., Sufit R. L., Brooks B. R. Pulmonary effects of thyrotropin-releasing hormone in amyotrophic lateral sclerosis. Lancet. 1984 Sep 1;2(8401):529–530. doi: 10.1016/s0140-6736(84)92616-3. [DOI] [PubMed] [Google Scholar]
  2. Brooke M. H., Florence J. M., Heller S. L., Kaiser K. K., Phillips D., Gruber A., Babcock D., Miller J. P. Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis. Neurology. 1986 Feb;36(2):146–151. doi: 10.1212/wnl.36.2.146. [DOI] [PubMed] [Google Scholar]
  3. Brooks B. R., Sufit R. L., Montgomery G. K., Beaulieu D. A., Erickson L. M. Intravenous thyrotropin-releasing hormone in patients with amyotrophic lateral sclerosis. Dose-response and randomized concurrent placebo-controlled pilot studies. Neurol Clin. 1987 Feb;5(1):143–158. [PubMed] [Google Scholar]
  4. Engel W. K., Siddique T., Nicoloff J. T. Effect on weakness and spasticity in amyotrophic lateral sclerosis of thyrotropin-releasing hormone. Lancet. 1983 Jul 9;2(8341):73–75. doi: 10.1016/s0140-6736(83)90060-0. [DOI] [PubMed] [Google Scholar]
  5. Guiloff R. J., Eckland D. J., Demaine C., Hoare R. C., MacRae K. D., Lightman S. L. Controlled acute trial of a thyrotrophin releasing hormone analogue (RX77368) in motor neuron disease. J Neurol Neurosurg Psychiatry. 1987 Oct;50(10):1359–1370. doi: 10.1136/jnnp.50.10.1359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Imoto K., Saida K., Iwamura K., Saida T., Nishitani H. Amyotrophic lateral sclerosis: a double-blind crossover trial of thyrotropin-releasing hormone. J Neurol Neurosurg Psychiatry. 1984 Dec;47(12):1332–1334. doi: 10.1136/jnnp.47.12.1332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Leopold N. A. Prolonged metoclopramide-induced dyskinetic reaction. Neurology. 1984 Feb;34(2):238–239. doi: 10.1212/wnl.34.2.238. [DOI] [PubMed] [Google Scholar]
  8. Mitsumoto H., Salgado E. D., Negroski D., Hanson M. R., Salanga V. D., Wilber J. F., Wilbourn A. J., Breuer A. C., Leatherman J. Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials. Neurology. 1986 Feb;36(2):152–159. doi: 10.1212/wnl.36.2.152. [DOI] [PubMed] [Google Scholar]
  9. Munsat T. L., Taft J., Kasdon D. Intrathecal thyrotropin-releasing hormone in amyotrophic lateral sclerosis. Neurol Clin. 1987 Feb;5(1):159–170. [PubMed] [Google Scholar]
  10. Ogawa N., Mizuno S., Nukina I., Tsukamoto S., Mori A. Chronic thyrotropin releasing hormone (TRH) administration on TRH receptors and muscarinic cholinergic receptors in CNS. Brain Res. 1983 Mar 21;263(2):348–350. doi: 10.1016/0006-8993(83)90328-1. [DOI] [PubMed] [Google Scholar]
  11. Serratrice G., Desnuelle C., Crevat A., Guelton C., Meyer-Dutour A. Traitement de la sclérose latérale amyotrophique par le facteur de libération de l'hormone thyréotrope (TRH). Rev Neurol (Paris) 1986;142(2):133–139. [PubMed] [Google Scholar]
  12. Simasko S. M., Horita A. Treatment of rats with the TRH analog MK-771. Down-regulation of TRH receptors and behavioral tolerance. Neuropharmacology. 1985 Feb;24(2):157–165. doi: 10.1016/0028-3908(85)90175-3. [DOI] [PubMed] [Google Scholar]
  13. Stober T., Schimrigk K., Dietzsch S., Thielen T. Intrathecal thyrotropin-releasing hormone therapy of amyotrophic lateral sclerosis. J Neurol. 1985;232(1):13–14. doi: 10.1007/BF00314033. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES